Kiora Pharmaceuticals (KPRX) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPRX | XTLB |
|---|---|---|
| Share price | $0.7202 | $1.37 |
| Market cap | $3.19M | $3.37M |
| 1-day change | -12.28% | -5.84% |
| YTD return | -63.44% | — |
| 1-year return | -61.49% | — |
| 5-year return | -99.87% | — |
| EPS (TTM) | $-2.72 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $451.00K |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-10.84M | $-1.03M |
| Gross margin | — | 0.67% |
| Operating margin | — | -481.60% |
| Net margin | — | -227.72% |
| 52-week high | $2.91 | $5.64 |
| 52-week low | $0.72 | $1.37 |
| Distance from 52-week high | -75.25% | -75.71% |
| Analyst consensus | none | — |
| Avg. price target upside | +1566.20% | — |
| Average volume | 35.23K | 6.58K |
| Shares outstanding | 4.42M | 2.46M |
| Employees | 13 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kiora Pharmaceuticals
KPRX stock →Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
KPRX vs XTLB FAQ
Which is bigger, Kiora Pharmaceuticals or XTL Biopharmaceuticals?
XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.19M for Kiora Pharmaceuticals (KPRX).
Are Kiora Pharmaceuticals and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.